ADCs	Antibody–drug conjugates
AE	adverse event
alloHSCT	allogeneic hematopoietic stem cell transplantation
AML	acute myeloid leukemia
AML-BFM	Acute Myeloid Leukemia Berlin-Frankfurt-Münster studies
ATAC	Assay for Transposase Accessible Chromatin
AZA	azacitidine
BCL-2	B-cell leukaemia/lymphoma 2
BiKEs	bispecific killer engager antibodies
BiTEs	bispecific T-engaging antibodies
CAR	chimeric antigen receptor
COG	Childhood Oncology Group
CR	complete remission
CRi	complete remission with incomplete blood count recovery
DAC	decitabine
DARTs	dual affinity retargets antibodies
DCOG	Dutch Childhood Oncology Group
DETs	differentially expressed protein-coding transcripts
DLT	dose-limiting toxicity
DNMT	DNA methyltransferase
EFS	event-free survival
FLT3-ITD	internal tandem duplication mutations in the juxtamembrane domain
FLT3-TKD	deletion in the tyrosine kinase domain
GO	Gemtuzumabozogamicin
HDACIs	histone deacetylase inhibitors
HDAC	Histone deacetylase
HLE	half-life extended
HMAs	hypomethylating agents
MRD	minimal residual disease
nd	no data
NIH	The National Institutes of Health
OS	overall survival
PDX	patient-derived xenografts
PPLLSG	Polish Pediatric Leukemia and Lymphoma Study Group
RFS	relapse-free survival
RTK	receptor tyrosine kinase
scFv	single-chain variable fragment
SD	standard deviation
SIRT	sirtuin protein family
SJCRH	St. Jude Children’s Research Hospital
TAA	tumor-associated antigen
Tregs	regulatory T cells
TriKEs	trispecific killer engager antibodies
TSG	tumor suppressor genes
WHO	World Health Organizatiοn